دورية أكاديمية
أعرض في EDS

Greater inhibition of female rat binge alcohol intake by adrenergic receptor blockers using a novel Two-Shot rat binge drinking model.

التفاصيل البيبلوغرافية
العنوان: Greater inhibition of female rat binge alcohol intake by adrenergic receptor blockers using a novel Two-Shot rat binge drinking model.
المؤلفون: De Oliveira Sergio T; Department of Psychiatry, Indiana University School of Medicine, 320 W. 15th Street, NB 300E, Indianapolis, IN, 46202, USA., Jane Smith R; Department of Psychiatry, Indiana University School of Medicine, 320 W. 15th Street, NB 300E, Indianapolis, IN, 46202, USA., Wean SE; Department of Psychiatry, Indiana University School of Medicine, 320 W. 15th Street, NB 300E, Indianapolis, IN, 46202, USA., Engleman EA; Department of Psychiatry, Indiana University School of Medicine, 320 W. 15th Street, NB 300E, Indianapolis, IN, 46202, USA., Hopf FW; Department of Psychiatry, Indiana University School of Medicine, 320 W. 15th Street, NB 300E, Indianapolis, IN, 46202, USA. whopf@iu.edu.
المصدر: Scientific reports [Sci Rep] 2024 Jun 18; Vol. 14 (1), pp. 14029. Date of Electronic Publication: 2024 Jun 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Binge Drinking*/drug therapy , Disease Models, Animal* , Rats, Wistar*, Animals ; Female ; Male ; Rats ; Ethanol ; Adrenergic Antagonists/pharmacology ; Naltrexone/pharmacology ; Propranolol/pharmacology ; Sex Factors ; Alcohol Drinking
مستخلص: Binge drinking (BD) contributes strongly to the harms of alcohol use disorder. Most rodent models do not result in binge-level blood alcohol concentrations (BACs), and to better understand individual and sex differences in neurobiological mechanisms related to BD, the use of outbred rat strains would be valuable. Here, we developed a novel BD model where after 3+ months of intermittent access to 20% alcohol Wistar rats drank, twice a week, with two 5-min intake (what we called Two-shot) separated by a 10-min break. Our findings showed during Two-Shot that most animals reached ≥ 80 mg% BAC levels (when briefly food-restricted). However, when increasing alcohol concentrations from 20 to 30%, 40%, or 50%, rats titrated to similar intake levels, suggesting rapid sensing of alcohol effects even when front-loading. Two-Shot drinking was reduced in both sexes by naltrexone (1 mg/kg), validating intake suppression by a clinical therapeutic agent for human problem drinking. Further, both propranolol (β-adrenergic receptor antagonist) and prazosin (α1-adrenergic receptor antagonist) reduced female but not male BD at the lower dose. Thus, our results provide a novel model for BD in outbred rats and suggest that female binging is more sensitive to adrenergic modulation than males, perhaps providing a novel sex-related therapy.
(© 2024. The Author(s).)
التعليقات: Update of: Res Sq. 2024 May 29:rs.3.rs-4402198. doi: 10.21203/rs.3.rs-4402198/v1. (PMID: 38853968)
References: Lancet. 2019 Aug 31;394(10200):781-792. (PMID: 31478502)
Addiction. 2006 Feb;101(2):212-22. (PMID: 16445550)
Addict Biol. 2019 May;24(3):426-437. (PMID: 29516676)
Front Psychiatry. 2023 Mar 24;14:1116901. (PMID: 37032937)
Alcohol. 2020 Dec;89:37-42. (PMID: 32712186)
Addict Biol. 2022 Mar;27(2):e13116. (PMID: 34856641)
Am J Psychiatry. 2017 Nov 1;174(11):1094-1101. (PMID: 28774194)
JAMA. 2018 Aug 28;320(8):815-824. (PMID: 30167705)
Alcohol Res. 2020 Aug 20;40(2):05. (PMID: 32832310)
Alcohol Alcohol. 2019 Jul 1;54(4):345-352. (PMID: 30888414)
JAMA Netw Open. 2022 Nov 1;5(11):e2239485. (PMID: 36318209)
Drug Alcohol Depend. 2019 Dec 1;205:107590. (PMID: 31600616)
Pharmacol Rev. 2016 Apr;68(2):242-63. (PMID: 26772794)
Biol Psychiatry. 2022 Jun 15;91(12):1008-1018. (PMID: 35430085)
J Neurochem. 2005 Jun;93(6):1469-81. (PMID: 15935063)
Prev Chronic Dis. 2014 Nov 20;11:E206. (PMID: 25412029)
Alcohol. 2008 Mar;42(2):91-7. (PMID: 18358987)
Pharmacol Biochem Behav. 2017 May;156:1-9. (PMID: 28347737)
Addict Biol. 2023 Sep;28(9):e13316. (PMID: 37644893)
Alcohol Clin Exp Res. 2012 May;36(5):881-6. (PMID: 21981346)
Alcohol Clin Exp Res. 2011 Jan;35(1):116-25. (PMID: 21039633)
Neuropharmacology. 2019 Oct;157:107681. (PMID: 31251994)
Addict Biol. 2019 Jul;24(4):664-675. (PMID: 29863763)
Addict Biol. 2011 Oct;16(4):600-14. (PMID: 21762292)
Lancet. 2009 Jun 27;373(9682):2223-33. (PMID: 19560604)
Br J Psychiatry. 1971 Dec;119(553):605-6. (PMID: 4947169)
Alcohol. 2014 May;48(3):243-52. (PMID: 24721195)
Drug Alcohol Depend. 2015 Nov 1;156:1-13. (PMID: 26371405)
Behav Brain Res. 2020 Sep 1;393:112768. (PMID: 32544510)
Curr Med Chem. 2017;24(24):2661-2670. (PMID: 27915987)
Neuropsychopharmacology. 2010 Jan;35(1):217-38. (PMID: 19710631)
Alcohol Clin Exp Res. 2008 Oct;32(10):1816-23. (PMID: 18671810)
Physiol Behav. 2016 Oct 15;165:77-85. (PMID: 27394659)
Alcohol Clin Exp Res. 2018 Feb;42(2):286-294. (PMID: 29205408)
Psychopharmacology (Berl). 2010 Oct;212(3):431-9. (PMID: 20676608)
Psychopharmacology (Berl). 2015 Aug;232(15):2647-57. (PMID: 25743758)
Alcohol Clin Exp Res. 2005 May;29(5):902-8. (PMID: 15897737)
Int J Mol Sci. 2021 Apr 06;22(7):. (PMID: 33917517)
Alcohol Clin Exp Res. 2009 Feb;33(2):264-72. (PMID: 19032582)
PLoS Med. 2019 Nov 26;16(11):e1002954. (PMID: 31770389)
Addict Behav. 2022 Sep;132:107347. (PMID: 35561632)
Arch Intern Med. 1989 May;149(5):1089-93. (PMID: 2719503)
Alcohol. 2014 May;48(3):225-34. (PMID: 24290311)
Neurosci Biobehav Rev. 2008;32(1):20-39. (PMID: 17617461)
Drug Alcohol Depend. 2005 Oct 1;80(1):105-16. (PMID: 16157233)
Biol Psychiatry. 2012 Nov 15;72(10):823-31. (PMID: 22817867)
Front Pharmacol. 2023 Jan 16;14:1076465. (PMID: 36726581)
Front Biosci (Landmark Ed). 2018 Jun 1;23(12):2255-2266. (PMID: 29772560)
Addict Biol. 2021 Jul;26(4):e12992. (PMID: 33331070)
Ann Intern Med. 1975 Aug;83(2):234-6. (PMID: 1096706)
JAMA Psychiatry. 2017 Sep 1;74(9):911-923. (PMID: 28793133)
Neuropsychopharmacology. 2021 Oct;46(11):1918-1926. (PMID: 34168279)
Neuropharmacology. 2022 May 1;208:108997. (PMID: 35176286)
Alcohol. 2014 May;48(3):253-64. (PMID: 24731992)
Biomed Pharmacother. 1992;46(9):419-24. (PMID: 1363375)
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Jul 13;133:111008. (PMID: 38641236)
Front Pharmacol. 2023 Mar 16;14:1146848. (PMID: 37007041)
Alcohol Clin Exp Res. 2003 Oct;27(10):1573-82. (PMID: 14574227)
Psychopharmacology (Berl). 2018 Jun;235(6):1625-1634. (PMID: 29460163)
Neuropharmacology. 2023 Aug 15;234:109545. (PMID: 37100382)
Am J Psychiatry. 2021 May 1;178(5):447-458. (PMID: 33207935)
JAMA Psychiatry. 2015 Aug;72(8):757-66. (PMID: 26039070)
معلومات مُعتمدة: R01 AA024109 United States AA NIAAA NIH HHS; R01 AA030710 United States AA NIAAA NIH HHS; AA024109 United States NH NIH HHS; AA030710 United States NH NIH HHS
المشرفين على المادة: 3K9958V90M (Ethanol)
0 (Adrenergic Antagonists)
5S6W795CQM (Naltrexone)
9Y8NXQ24VQ (Propranolol)
تواريخ الأحداث: Date Created: 20240618 Date Completed: 20240618 Latest Revision: 20240701
رمز التحديث: 20240701
مُعرف محوري في PubMed: PMC11189554
DOI: 10.1038/s41598-024-64565-9
PMID: 38890353
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-64565-9